Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Samsung Bioepis
Pharma
Eisai, ex-NMPA official, Pfizer-Summit—Fierce Pharma Asia
Eisai initiated a U.S. restructuring program. A former China NMPA deputy director is under investigation. Pfizer formed a collaboration with Summit.
Angus Liu
Feb 28, 2025 8:45am
J&J sues Samsung Bioepis over Stelara biosimilar agreement
Feb 25, 2025 10:21am
Regeneron loses bid to block Amgen's Eylea biosim, sinking shares
Sep 24, 2024 10:32am
Samsung Biologics' 37% sales surge propelled by biosimilars
Jul 24, 2024 10:56am
Humira's market share slips as biosimilars start to catch on
Jul 12, 2024 11:51am
Italy opens antitrust case against Novartis, Biogen and others
Jun 6, 2024 11:39am
